ANI Pharmaceuticals, Inc. $ANIP Position Boosted by Penn Capital Management Company LLC

Penn Capital Management Company LLC boosted its holdings in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) by 15.4% during the 2nd quarter, Holdings Channel reports. The fund owned 207,362 shares of the specialty pharmaceutical company’s stock after acquiring an additional 27,646 shares during the quarter. Penn Capital Management Company LLC’s holdings in ANI Pharmaceuticals were worth $17,183,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also recently added to or reduced their stakes in the business. Maryland State Retirement & Pension System boosted its position in ANI Pharmaceuticals by 5.4% during the 4th quarter. Maryland State Retirement & Pension System now owns 2,613 shares of the specialty pharmaceutical company’s stock worth $206,000 after acquiring an additional 134 shares during the period. The Manufacturers Life Insurance Company increased its holdings in shares of ANI Pharmaceuticals by 1.5% during the first quarter. The Manufacturers Life Insurance Company now owns 9,577 shares of the specialty pharmaceutical company’s stock valued at $736,000 after purchasing an additional 143 shares during the period. CANADA LIFE ASSURANCE Co increased its holdings in shares of ANI Pharmaceuticals by 1.0% during the second quarter. CANADA LIFE ASSURANCE Co now owns 19,408 shares of the specialty pharmaceutical company’s stock valued at $1,267,000 after purchasing an additional 198 shares during the period. Oregon Public Employees Retirement Fund increased its holdings in shares of ANI Pharmaceuticals by 5.1% during the fourth quarter. Oregon Public Employees Retirement Fund now owns 4,086 shares of the specialty pharmaceutical company’s stock valued at $323,000 after purchasing an additional 200 shares during the period. Finally, Federation des caisses Desjardins du Quebec raised its stake in shares of ANI Pharmaceuticals by 0.6% during the fourth quarter. Federation des caisses Desjardins du Quebec now owns 39,391 shares of the specialty pharmaceutical company’s stock valued at $3,110,000 after purchasing an additional 221 shares in the last quarter. Institutional investors own 76.05% of the company’s stock.

ANI Pharmaceuticals Stock Down 0.9%

ANIP opened at $72.83 on Friday. ANI Pharmaceuticals, Inc. has a one year low of $70.15 and a one year high of $99.50. The company has a debt-to-equity ratio of 0.99, a quick ratio of 2.41 and a current ratio of 2.91. The stock’s fifty day moving average is $79.68 and its 200-day moving average is $78.65. The company has a market capitalization of $1.67 billion, a PE ratio of 15.70 and a beta of 0.44.

ANI Pharmaceuticals (NASDAQ:ANIP) last announced its earnings results on Friday, August 7th. The specialty pharmaceutical company reported $2.21 earnings per share for the quarter, beating the consensus estimate of $2.04 by $0.17. The business had revenue of $266.04 million during the quarter, compared to analysts’ expectations of $260.13 million. ANI Pharmaceuticals had a return on equity of 27.37% and a net margin of 11.07%.The company’s quarterly revenue was up 25.8% on a year-over-year basis. During the same quarter last year, the business posted $1.80 earnings per share. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. On average, equities analysts predict that ANI Pharmaceuticals, Inc. will post 7.83 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts recently weighed in on ANIP shares. Guggenheim reduced their price objective on shares of ANI Pharmaceuticals from $124.00 to $119.00 and set a “buy” rating for the company in a report on Monday, August 10th. Zacks Research cut shares of ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Thursday, May 14th. Weiss Ratings lowered shares of ANI Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Tuesday, August 11th. Canaccord Genuity Group reduced their price target on shares of ANI Pharmaceuticals from $91.00 to $90.00 and set a “hold” rating for the company in a research note on Monday, August 10th. Finally, Wall Street Zen cut shares of ANI Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Saturday, August 8th. Four research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $105.83.

Insider Buying and Selling

In other news, VP Meredith Cook sold 500 shares of the firm’s stock in a transaction on Thursday, August 13th. The stock was sold at an average price of $75.48, for a total transaction of $37,740.00. Following the completion of the sale, the vice president directly owned 74,424 shares of the company’s stock, valued at $5,617,523.52. This trade represents a 0.67% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Nikhil Lalwani sold 5,400 shares of the stock in a transaction on Tuesday, August 25th. The shares were sold at an average price of $74.30, for a total value of $401,220.00. Following the completion of the transaction, the chief executive officer owned 344,489 shares of the company’s stock, valued at $25,595,532.70. This trade represents a 1.54% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 24,387 shares of company stock worth $1,947,625 in the last ninety days. Insiders own 8.10% of the company’s stock.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.